SM
ADMS

Sabby Management’s Adamas Pharmaceuticals ADMS Stock Holding History

Sabby Management’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-553
Closed -$61K – 216
2021
Q2 		$61K Buy
+553
New +$2.86K 0.01% 157
2016
Q1 		– Sell
-243
Closed -$688K – 376
2015
Q4 		$688K Buy
+243
New +$4.09K 0.04% 217

Other funds holding ADMS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
CCPM
Cooper Creek Partners Management New York $2.92B AUM 30.49% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Sabby Management's ADMS Position: Q4 2016 in Review

Sabby Management sold out of Adamas Pharmaceuticals (ADMS) in Q4 2016, closing a stake of 28,200 shares — an estimated $463K sold.

Sabby Management first reported a position in ADMS in Q3 2015 and held it in 4 quarters. The position peaked at $2.89M in Q1 2016. 78 funds tracked by Wall St. Rank hold ADMS as of Q4 2016.

  • Sabby Management reported no remaining Adamas Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • Sabby Management sold 28,200 Adamas Pharmaceuticals shares in Q4 2016, an estimated $463K.
  • Sabby Management first reported a position in Adamas Pharmaceuticals in Q3 2015 and held it in 4 quarters.
  • Sabby Management's Adamas Pharmaceuticals position peaked at $2.89M in Q1 2016.
  • 78 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q4 2016.

Based on Sabby Management's 13F filing for Q4 2016, filed 14 Feb 2017.